Abacus Medicine Pharma Services (‘Abacus’) announces the signing of a partnership agreement with Mirum Pharmaceuticals, Inc. (‘Mirum’) for the commercialization of LIVMARLI® (maralixibat) oral solution in the Nordic markets. Under the terms of the agreement, Mirum has appointed Abacus to exclusively promote, market, sell, distribute, and commercialize LIVMARLI in the territory of Denmark, Finland, Iceland, Norway, and Sweden.

LIVMARLI is an orally administered, ileal bile acid transporter (IBAT) inhibitor approved with orphan designation in Europe to treat patients aged 2 months and older with cholestatic pruritus caused by Alagille syndrome (ALGS), as well as to treat patients aged 3 months and older with progressive familial intrahepatic cholestasis (PFIC). ALGS and PFIC are inherited, life-threatening rare diseases in which bile cannot drain properly from the liver, resulting in a build-up of bile acid in the liver and blood. This accumulation can cause progressive liver damage, cirrhosis, and end-stage liver disease.

Gary Kahn, Vice President of Business Development for Abacus Medicine Pharma Services, said: “We are thrilled to partner with Mirum Pharmaceuticals to introduce a treatment option for patients that suffer from these debilitating rare liver diseases. This partnership underscores the shared vision and joint commitment of both companies to bring a meaningful medication to those who need them most. Our combined expertise and resources will enable us to make substantial progress in addressing the challenges faced by the ALGS and PFIC communities in the Nordics.”